Vascudyne

Executive Summary

Vascudyne is a US-based biotechnology company founded in 2016 that specializes in developing regenerative, tissue-engineered vascular grafts for cardiovascular surgery. The company's platform technology creates 100% biological, non-immunogenic tissues intended to address critical needs in coronary artery bypass, heart valve replacement, and vascular repair. By leveraging tissue engineering principles, Vascudyne aims to overcome limitations of synthetic grafts and autologous vessels, offering off-the-shelf availability and reduced risk of rejection. The company remains in a pre-commercial stage, focused on preclinical development and early regulatory pathways.

Upcoming Catalysts (preview)

• Q3 2026Preclinical study results (e.g., patency and remodeling data)70% success
• Q4 2026Series B financing to advance toward IND-enabling studies50% success
• H1 2027IND submission for first-in-human trial of vascular graft30% success